explore -WSS

explore

author：focus 2025-10-02 03:24:26 - browse：16

Cambridge: Biogen — Ruby Wallau for STAT

Biogen, the iconic but embattled biotech firm, is shuttering Biogen Digital Health, its roughly 150-person group focused on using new types of data like those from mobile phones and smart watches, and ending a clinical trial being conducted with Apple early, STAT has learned.

Biogen confirmed the organizational change, but said it might lean even more on digital tech startups in the future.

“It’s certainly not an abandonment of digital, it’s more of a realignment of resources and priorities,” said Adam Keeney, Biogen’s executive vice president and head of corporate development. However, he later acknowledged, Biogen Digital Health, a separate entity, “would no longer continue in its current form.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Yancopoulos of Regeneron works to expand Dupixent success

WSS

CRISPR technology availability, affordability needs to be expanded

Erich Jarvis studies song birds to learn about human stuttering

Testing for cancer recurrence creates a new limbo for patients

Meta's Zuckerberg and Chan on track to put $50 billion into science

Testing GLP

Asbestos ban is immediate, but health effects will linger for decades

knowledge

explore

focus

Peter Hotez and the public health issue of online harassment

Pregnancy ages women, but effects reverse after delivery

Novavax promises a turnaround & Lilly roils the obesity market

WHO may add ‘noma' to its list of neglected tropical diseases

Duchenne breakthrough therapy leaves behind pioneering families

Steward Health Care expansion into Malta flopped

Continuity nursing helped my family in our darkest PICU moments

Cancer, immunology, HIV research ensnared in fetal tissue politics

United colonoscopy coverage change 'may cost lives,' doctors say

Biden's order seeks to regulate AI risk without stifling innovation

hotspot

Feng Zhang suggests Editas didn’t move quickly enough to find product targets

Medtronic CEO on promising devices for diabetes, hypertension

Testing GLP

Cassava reveals details — and problems — with Alzheimer's study

Yancopoulos of Regeneron works to expand Dupixent success

Readout LOUD podcast, live from the STAT Breakthrough Summit East

Wikipedia

focus

hotspot

Wikipedia